United States · Markets & Finance · Barron's

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing 40% Layoffs

Published by Barron's · United States 13 h ago

Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.

Read the full article on Barron's Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)

Also worth reading

Uranium Hits Record High While Nuclear Stocks Slide

Crypto for Advisors: The CLARITY Act failed, but the rules came anyway

Court overturns $22.7M patent infringement award against Gogo

California legalizes plug-in balcony solar panels for renters and homeowners

Trump’s Threat to Ban Diesel Exports Sets Off Global Alarms

Business Insider

How to tell if you qualify for Trump's $500 ACA refund check, and what states are getting them